Showing 1 - 2 results of 2 for search 'Y. El-Bahy', query time: 0.02s Refine Results
  1. 1
    Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

    Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) by J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, J. Routy, C. Wyen, M. Ait-Khaled, M. Nascimento, K. Pappa, R. Wang, J. Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, K. Smith, Y. El-Bahy

    Published 2020-02-01
    Get full text
    Article
  2. 2
    Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

    Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies by P. Cahn, J. Sierra Madero, J. Arribas, A. Antinori, R. Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, J. Sievers, C. Man, R. Urbaityte, M. Underwood, A. Tenorio, K. Pappa, B. Wynne, M. Gartland, M. Aboud, J. van Wyk, K. Smith, Y. El-Bahy

    Published 2020-02-01
    Get full text
    Article

Search Tools: